Literature DB >> 16195541

Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.

Yinglin Liu1, Barry L Fanburg.   

Abstract

We have previously found that both mitogen-activated protein kinase (MAPK)- and Rho kinase (ROCK)-related signaling pathways are necessary for the induction of pulmonary artery smooth muscle cell (SMC) proliferation by serotonin (5-hydroxytryptamine [5-HT]). In the present study, we investigated the possible additional participation of a phosphatidylinositol 3-kinase (PI3K)/serine-threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/p70 ribosomal S6 kinase (S6K1) pathway in this growth response. We found transient activation of Akt (Ser473) and more prolonged activation of S6K1 by 5-HT. Inhibition of PI3K with Wortmannin and LY294002 completely blocked these activations, but not that of MAPK or the ROCK substrate myosin phosphatase targeting subunit. Similarly, inhibition of MAPK and ROCK failed to block the Akt activation. Inhibition of Akt with NL-71-101 and downregulation of Akt expression with Akt small interfering RNA blocked 5-HT-induced S6K1 phosphorylation. Wortmannin, LY294002, and NL-71-101 dose-dependently inhibited 5-HT-induced SMC proliferation. 5-HT stimulated mTOR phosphorylation and the mTOR inhibitor, rapamycin, blocked activations of S6K1 and S6 ribosomal protein, and inhibited 5-HT-induced SMC proliferation. Akt phosphorylation and cell proliferation were also blocked by the antioxidants, N-acetyl-l-cysteine, Ginko biloba 501, and tiron, the reduced nicotinamide adenine dinucleotide phosphate oxidase inhibitor, diphenyleneiodonium, and the 5-HT2 receptor antagonists ketanserin and mianserin, but not by the 5-HT serotonin transporter or 5-HT 1B/1D receptor antagonists. We conclude from these studies that a parallel PI3K- and reactive oxygen species-dependent Akt/mTOR/S6K1 pathway participates independently from MAPK and Rho/ROCK in the mitogenic effect of 5-HT on pulmonary artery SMCs. From these and other studies, we postulate that independent signaling pathways leading to 5-HT-induced SMC proliferation are initiated through multiple 5-HT receptors and serotonin transporter at the cell surface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195541      PMCID: PMC2644181          DOI: 10.1165/rcmb.2005-0163OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  59 in total

1.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

2.  Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation.

Authors:  Céline Dugourd; Marianne Gervais; Pierre Corvol; Catherine Monnot
Journal:  Hypertension       Date:  2003-03-03       Impact factor: 10.190

3.  Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle.

Authors:  A Banes; J A Florian; S W Watts
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

4.  Involvements of voltage-independent Ca2+ channels and phosphoinositide 3-kinase in endothelin-1-induced PYK2 tyrosine phosphorylation.

Authors:  Yoshifumi Kawanabe; Nobuo Hashimoto; Tomoh Masaki
Journal:  Mol Pharmacol       Date:  2003-04       Impact factor: 4.436

5.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.

Authors:  J-M Launay; P Hervé; K Peoc'h; C Tournois; J Callebert; C G Nebigil; N Etienne; L Drouet; M Humbert; G Simonneau; L Maroteaux
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

6.  Redox stress regulates cell proliferation and apoptosis of human hepatoma through Akt protein phosphorylation.

Authors:  Shi Dong-Yun; Deng Yu-Ru; Liu Shan-Lin; Zhang Ya-Dong; Wei Lian
Journal:  FEBS Lett       Date:  2003-05-08       Impact factor: 4.124

Review 7.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

8.  Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.

Authors:  Elisabeth Marcos; Serge Adnot; Minh Hien Pham; Anne Nosjean; Bernadette Raffestin; Michel Hamon; Saadia Eddahibi
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

9.  Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis.

Authors:  Surabhi Dangi; Hyukjin Cha; Paul Shapiro
Journal:  Cell Signal       Date:  2003-07       Impact factor: 4.315

10.  Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

Authors:  Andrew R Tee; Brendan D Manning; Philippe P Roux; Lewis C Cantley; John Blenis
Journal:  Curr Biol       Date:  2003-08-05       Impact factor: 10.834

View more
  31 in total

1.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

2.  Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

Authors:  Guillaume Gary-Bobo; Amal Houssaini; Valerie Amsellem; Dominique Rideau; Pierre Pacaud; Aline Perrin; Jérémy Brégeon; Elisabeth Marcos; Jean-Luc Dubois-Randé; Olivier Sitbon; Laurent Savale; Serge Adnot
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

Review 3.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

4.  JNK regulates serotonin-mediated proliferation and migration of pulmonary artery smooth muscle cells.

Authors:  Lin Wei; Yinglin Liu; Hideaki Kaneto; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-12       Impact factor: 5.464

5.  Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts.

Authors:  K M Mair; M R MacLean; I Morecroft; Y Dempsie; T M Palmer
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

6.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Authors:  Amal Houssaini; Shariq Abid; Nathalie Mouraret; Feng Wan; Dominique Rideau; Mirna Saker; Elisabeth Marcos; Claire-Marie Tissot; Jean-Luc Dubois-Randé; Valérie Amsellem; Serge Adnot
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 7.  mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

Authors:  Elena A Goncharova
Journal:  FASEB J       Date:  2013-01-25       Impact factor: 5.191

8.  Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells.

Authors:  Y Liu; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

9.  The 5-hydroxytryptamine transporter is functional in human coronary artery smooth muscle cells proliferation and is regulated by Interleukin-1 beta.

Authors:  Qing-Jie Wang; Dong Wang; Cheng-Chun Tang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension.

Authors:  Aiko Ogawa; Amy L Firth; Weijuan Yao; Michael M Madani; Kim M Kerr; William R Auger; Stuart W Jamieson; Patricia A Thistlethwaite; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-24       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.